NEW YORK – Three investment banks on Monday initiated coverage of rare disease genetic testing and services company Centogene with bullish outlooks.
BTIG initiated coverage of Rostock, Germany-based Centogene with a Buy rating on its stock and an $18 price target, while SVB Leerink rated the firm's shares Outperform and put a price target of $21. Evercore ISI began coverage of Centogene with an Outperform rating on its stock and a $17 price target.